Providing a trusted benchmark of genuine research influence through rigorous evaluation and selection, at a time when research integrity matters more than ever LONDON, Nov. 18, 2026 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today released the Highly Cited Researchers 2026 list, a trusted benchmark of research influence amidst growing scrutiny of research integrity. Based on stringent standards of selection and evaluation, as well as expert analysis, the annual list recognizes researchers whose contributions have demonstrated broad and significant influence in their fields.
LONDON, Nov. 12, 2026 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT) ("Clarivate"), a leading global provider of transformative intelligence, today announced the expiration and final results of its previously announced cash tender offers (collectively, the "Offers") by its wholly-owned subsidiary, Clarivate Science Holdings Corporation (the "Company"), to purchase the outstanding 3.875% Senior Secured Notes due 2028 (the "2028 Notes") for aggregate principal amount of up to $400,000,000 (the "2028 Notes Series Cap") and the outstanding 4.875% Senior Notes due 2029 (the "2029 Notes" and, together with the 2028 Notes, the "Notes" and, each, a "Series of Notes") for aggregate principal amount of up to $100,000,000 (the "2029 Notes Series Cap" and, together with the 2028 Notes Series Cap, each, a "Series Cap"), in each case upon the terms and subject to the conditions set forth in the Offer to Purchase dated November 4, 2026 (the "Offer to Purchase") and any related documents (collectively with the Offer to Purchase, the "Tender Offer Documents"). Additionally, the Company has exercised its right to increase the aggregate principal amount of 2028 Notes and 2029 Notes accepted for purchase by 2% of the outstanding aggregate principal amount of each Series of Notes, and as a result, will accept for purchase $533,000,000 total aggregate principal amount of the Notes, with the tendered 2028 Notes and 2029 Notes accepted at a proration factor of approximately 67.9% and 45.5%, respectively.
LONDON, Nov. 11, 2026 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, announced today that Matti Shem Tov, Chief Executive Officer, and Michael Easton, Executive Vice President and Chief Financial Officer, will present at the RBC Capital Markets Global Technology, Internet, Media and Telecommunications Conference, on Wednesday, November 18, 2026 at 2:00 pm Eastern Time. The live webcast can be accessed at https://kvgo.com/rbc/clarivate-plc-november-2026 and will be available for replay.
New Derwent patent and Darts-ip litigation connections give IP professionals access to curated patent and litigation intelligence alongside CompuMark trademark data BARCELONA, Spain, Nov. 11, 2026 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced that trusted patent and litigation intelligence from Clarivate is now available via Claude through IPOne, giving intellectual property (IP) professionals access to authoritative IP data within the AI workflows they already use. The IPOne Derwent patent and Darts-ip litigation data connectors are now listed on Anthropic's marketplace.
/PRNewswire/ -- Clarivate Plc (NYSE: CLVT) ("Clarivate"), a leading global provider of transformative intelligence, today announced the Reference Yield with
LONDON, Nov. 10, 2026 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT) ("Clarivate"), a leading global provider of transformative intelligence, today announced the Reference Yield with respect to the 2028 Notes and the 2028 Notes Total Consideration (as set forth in the table below) to be paid in connection with its previously announced cash tender offers (collectively, the "Offers") by its wholly-owned subsidiary, Clarivate Science Holdings Corporation (the "Company"), to purchase the outstanding notes described below, in each case upon the terms and subject to the conditions set forth in the Offer to Purchase dated November 4, 2026 (the "Offer to Purchase"). The Company is offering to purchase in the Offers its 3.875% Senior Secured Notes due 2028 (the "2028 Notes") and its 4.875% Senior Notes due 2029 (the "2029 Notes" and, together with the 2028 Notes, the "Notes" and, each, a "Series of Notes") for the applicable consideration described below, subject to a $500,000,000 cap on the aggregate principal amount of Notes purchased in the Offers (the "Tender Cap"), proration and the terms and conditions set forth in the Offer to Purchase, including, among others, a $400,000,000 cap on the aggregate principal amount of the 2028 Notes to be purchased and a $100,000,000 cap on the aggregate principal amount of the 2029 Notes to be purchased pursuant to the Offers (each, a "Series Cap").
Clarivate PLC shares surged 40% after a solid Q3 and $600M life sciences divestment, reducing leverage and sharpening business focus. Clarivate now trades at modest valuations—2.6x sales, under 6x EBITDA, and about 3x earnings—despite only slight organic growth and persistent leverage risks. Forward guidance projects net leverage falling to 3.5–3.6x and free cash flow rising to $350–$400M by 2027, supporting a more manageable debt profile.
/PRNewswire/ -- Clarivate Plc (NYSE: CLVT) ("Clarivate"), a leading global provider of transformative intelligence, today announced that its wholly-owned
LONDON, Nov. 4, 2026 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT) ("Clarivate"), a leading global provider of transformative intelligence, today announced that its wholly-owned subsidiary, Clarivate Science Holdings Corporation (the "Company"), has commenced cash tender offers (collectively, the "Offers") to purchase the outstanding notes described below, in each case upon the terms and subject to the conditions set forth in the Offer to Purchase dated November 4, 2026 (the "Offer to Purchase"). The Company is offering to purchase in the Offers its 3.875% Senior Secured Notes due 2028 (the "2028 Notes") and its 4.875% Senior Notes due 2029 (the "2029 Notes" and, together with the 2028 Notes, the "Notes" and, each, a "Series of Notes") for the applicable consideration described below, subject to a $500,000,000 cap on the aggregate principal amount of Notes purchased in the Offers (the "Tender Cap"), proration and the terms and conditions, including, among others, a $400,000,000 cap on the aggregate principal amount of the 2028 Notes to be purchased and a $100,000,000 cap on the aggregate principal amount of the 2029 Notes to be purchased pursuant to the Offers (each, a "Series Cap") set forth in the Offer to Purchase.
Clarivate NYSE: CLVT said it completed the sale of its Life Sciences & Healthcare segment ahead of schedule during the third quarter, leaving the company focused on its Academia & Government and Intellectual Property businesses. Management said the reshaped company has approximately $2 billion in revenue, with recurring organic revenue representing 93% of the total.